

Application No.: 09/657,336

2

Docket No.: 500862001500

AMENDMENTS TO THE CLAIMS

Claim 1 (Currently amended): A modified anti-viral peptide comprising a peptide having been modified to contain a maleimide containing group which is reactive with cysteine 34 of serum albumin to form a stable covalent bond, wherein said peptide comprising comprises an amino acid sequence wherein said sequence is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545, wherein said sequence exhibiting exhibits an anti-viral activity against human immunodeficiency virus (HIV) wherein and said peptide is covalently bonded to cysteine 34 of serum albumin through said maleimide containing group, wherein the ratio of peptide to serum albumin is 1:1.

Claim 2 (canceled)

Claim 3 (canceled)

Claim 4 (Currently amended) The modified peptide of claim 1 wherein said peptide is DP 107 and comprises the amino acid sequence [[of]] is SEQ ID NO:2.

Claim 5 (canceled)

Claim 6 (Currently amended): The modified peptide of claim 1 wherein said peptide amino acid sequence is selected from the group consisting of SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545.

Claims 7-18 (canceled)

Claim 19 (Currently amended): A composition for use in the prevention and/or treatment of acquired immune deficiency syndrome (AIDS) comprising, in a physiologically

sf-2050052

BEST AVAILABLE COPY